Sacituzumab govitecan

MEDSIR & Debiopharm Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer

Retrieved on: 
火曜日, 5月 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, Patient, Infection, Prognosis, WEE1, HER2, Clinical trial, University, Diagnosis, AACR, Safety, Breast cancer, Sacituzumab govitecan, ADC, Gilead Sciences, HR, Breast, Metastasis, Cell, Mortality, IST, PR, University of Bristol, TNBC, Pharmaceutical industry

Hormone receptor-positive (HR+)/HER2- is the most common type of breast cancer and it accounts for 70% of all breast cancers.

Key Points: 
  • Hormone receptor-positive (HR+)/HER2- is the most common type of breast cancer and it accounts for 70% of all breast cancers.
  • “It’s great to see companies like Debiopharm that are open to investigating novel combination strategies to support breast cancer patients.
  • “We are honored to develop this Investigator Sponsor Trial (IST) in collaboration with Debiopharm and Gilead to explore new approaches to breast cancer treatment.
  • The foundations for this clinical trial were set by the promising preclinical data suggesting an existing synergy between Debiopharm’s Debio 0123 and Gilead’s sacituzumab govitecan.

Royalty Pharma Reports First Quarter 2024 Results

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Ulcerative colitis, KarXT, Food, MorphoSys, European Commission, Marketing, New Drug Application, Cystic fibrosis, PDSS, PANSS, Tourette syndrome, Lupus, Docetaxel, Roche, Schizophrenia, Novartis, ADP, Pfizer, Incidence, Bristol Myers Squibb, Patient, Neurology, Acquisition, Sacituzumab govitecan, Olanzapine, Civil service commission, Multiple sclerosis, Positive, Vertex, Sanofi, Teva Pharmaceuticals, Astellas Pharma, European Medicines Agency, Lung cancer, Pharmaceutical industry

During 2024, Royalty Pharma announced new transactions of up to $619 million.

Key Points: 
  • During 2024, Royalty Pharma announced new transactions of up to $619 million.
  • In January 2024, Royalty Pharma acquired a royalty interest in ecopipam for an upfront payment of $49 million and up to $44 million in milestone payments contingent on the achievement of certain regulatory milestones.
  • In May 2024, Royalty Pharma announced a transaction to acquire royalties and milestones on frexalimab owned by ImmuNext for approximately $525 million in cash including estimated transaction costs.
  • Royalty Pharma has provided guidance for full year 2024, excluding transactions and borrowings announced after the date of this release, as follows:

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
木曜日, 4月 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
木曜日, 4月 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.

Royalty Pharma Reports Q4 and Full Year 2023 Results

Retrieved on: 
木曜日, 2月 15, 2024
MorphoSys, Pfizer, European Commission, Recurrence, Docetaxel, Roche, Cystic fibrosis, Share repurchase, FDA, Food, Schizophrenia, Growth, Sacituzumab govitecan, PTC, Vertex, Astellas Pharma, Risdiplam, Metastasis, Projection, KarXT, Bristol Myers Squibb, PTC Therapeutics, Endocrine gland, Lung cancer, Civil service commission, JAK, Therapy, Tourette syndrome, Webcast, Patient, Cytokinetics, Eastern Time Zone, Novartis, Ruxolitinib, NDA, Pharmaceutical industry

In October 2023, Royalty Pharma drew $350 million under its existing unsecured revolving credit facility, which was repaid during the fourth quarter of 2023.

Key Points: 
  • In October 2023, Royalty Pharma drew $350 million under its existing unsecured revolving credit facility, which was repaid during the fourth quarter of 2023.
  • Royalty Pharma began repurchasing its Class A ordinary shares in April 2023 under a $1.0 billion multi-year share repurchase program.
  • During the fourth quarter of 2023, Royalty Pharma announced new transactions of up to $1.6 billion.
  • Royalty Pharma will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2023 results today at 8:00 a.m., Eastern Time.

Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023

Retrieved on: 
木曜日, 11月 30, 2023
Oncology, Health, Consumer, Hospitals, Women, Pharmaceutical, Biotechnology, Data, Research, Senior, ADC, Patient, MBC, Breast, Caregiver, MD, Survival, Doctor of Philosophy, Quality of life, Science, TNBC, Sacituzumab govitecan

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.
  • “Trodelvy is the first approved Trop-2-directed ADC to significantly improve survival in both second-line metastatic TNBC and pre-treated HR+/HER2- metastatic breast cancer,” said Bill Grossman, MD, PhD, Senior Vice President, Therapeutic Area Head, Gilead Oncology.
  • “The data being presented at SABCS add to the breadth of evidence reinforcing Trodelvy's use in these two difficult-to-treat breast cancers.
  • Additionally, the real-world data being presented in metastatic breast cancer provide insights on quality of life and other measures of health to inform both providers and patients in making treatment decisions.”

Gilead Sciences Announces Third Quarter 2023 Financial Results

Retrieved on: 
火曜日, 11月 7, 2023
Biotechnology, Pharmaceutical, AIDS, Oncology, General Health, Health, Infectious Diseases, Hospitals, BIRCH, Food, Pembrolizumab, B-cell lymphoma, Impact of the COVID-19 pandemic on hospitals, EPS, COVID-19, Tax rate, ETR, CAPELLA, Cohort study, Infection, Acute lymphoblastic leukemia, American Association for the Study of Liver Diseases, SARS-CoV-2, Earnings per share, HIV, GAAP, HCV, Safety, Patient, Food and Drug Administration, European Commission, Conference, Obeldesivir, Research, Growth, European, Lung cancer, Total, HDV, PD-L1, Research and development, Incidence, Hepatology, Axicabtagene ciloleucel, Omicron, Liver, Lung, Risk, Science, FTC, Table, Liver disease, HBV, Pharmaceutical industry, Video game, Fine chemical, Security (finance), Virology, Sacituzumab govitecan, Remdesivir

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.
  • During the third quarter of 2023, Gilead generated $1.8 billion in operating cash flow.
  • During the third quarter of 2023, Gilead repaid $2.3 billion of debt, paid dividends of $953 million and repurchased $300 million of common stock.
  • Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.

Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023

Retrieved on: 
月曜日, 10月 16, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Clinical Trials, Congress, Neoplasm, Multimedia, Cancer, Senior, Doctor of Philosophy, HNSCC, MD, ESMO, B-cell lymphoma, Carcinoma, CAR, Head, TNBC, European Society for Medical Oncology, MBC, Patient, Dana–Farber Cancer Institute, Pharmaceutical industry, Sacituzumab govitecan, Axicabtagene ciloleucel

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present new data, including three oral presentations, at the European Society for Medical Oncology (ESMO) Congress 2023.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present new data, including three oral presentations, at the European Society for Medical Oncology (ESMO) Congress 2023.
  • Kite will also present analyses supporting the use of Yescarta® (axicabtagene ciloleucel) in relapsed/refractory large B-Cell lymphoma (LBCL).
  • View the full release here: https://www.businesswire.com/news/home/20231015111917/en/
    “Our data at ESMO 2023 reflect a broad clinical development program in difficult-to-treat cancers,” said Bill Grossman, MD, PhD, Senior Vice President, Therapeutic Area Head, Gilead Oncology.
  • “We believe our data will help further clinicians’ understanding of when to use Yescarta in these patients and reinforce confidence in CAR T-cell therapies overall.”

Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer

Retrieved on: 
日曜日, 9月 10, 2023
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Senior, Diarrhea, IO, DCR, Lung cancer, International Association, Cohort study, NSCLC, Doctor of Philosophy, TPS, Sepsis, Yonsei University, Dor, Phase 3, Patient, Division, Anemia, Weakness, Science, Pembrolizumab, Death, Safety, PD-L1, Conference, ORR, Pharmaceutical industry, Cohort, MD, Merck, Sacituzumab govitecan

The results are being presented today at the IASLC 2023 World Conference on Lung Cancer (#WCLC23) hosted by the International Association for the Study of Lung Cancer.

Key Points: 
  • The results are being presented today at the IASLC 2023 World Conference on Lung Cancer (#WCLC23) hosted by the International Association for the Study of Lung Cancer.
  • In Cohort A (n=29), confirmed and unconfirmed objective response rate (ORR) was 69%, and disease control rate (DCR) was 86%.
  • In Cohort B (n=32), confirmed and unconfirmed ORR was 44%, and DCR was 78%.
  • Trodelvy has a Boxed Warning for severe or life-threatening neutropenia and severe diarrhea; please see below for additional Important Safety Information.

Royalty Pharma Reports Second Quarter 2023 Results

Retrieved on: 
火曜日, 8月 8, 2023
Acceleration, Net, Pressure, University, Civil service commission, Astellas Pharma, Chronic lymphocytic leukemia, Vertex, Calendar, Aplastic anemia, DPP, GAAP, Leuprorelin, Sale, Ulcerative colitis, Psoriasis, Gilead, EBITDA, Acquisition, European Commission, Patient, Risk, Metastasis, Cystic fibrosis, Growth, Johnson & Johnson, California Miramar University, FDA, Sacituzumab govitecan, Regulation of tobacco by the U.S. Food and Drug Administration, Death, Food, Ivacaftor, Pfizer, Talazoparib, Bank, Video game, Music, Vaccine, Pharmaceutical industry, Real estate, Cryptocurrency, Berotralstat, Apalutamide, Nusinersen, Elexacaftor/tezacaftor/ivacaftor, Adjustment, Guselkumab, Ibrutinib

Drivers of total royalty receipts in the second quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).

Key Points: 
  • Drivers of total royalty receipts in the second quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
  • Royalty Pharma acquired a royalty interest in Trelegy in July 2022 and began receiving royalty receipts in the third quarter of 2022.
  • During the second quarter of 2023, Royalty Pharma began repurchasing its Class A ordinary shares and repurchased approximately four million shares for $134 million.
  • The weighted-average diluted Class A ordinary shares outstanding for the second quarter of 2023 was 606 million as compared to 607 million for the first quarter of 2023.